DAXOR CORP 10-Q Summary: Quarter Ended September 30, 1995
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 1995, and the nine-month period ended on the same date. DAXOR Corporation operates clinical laboratories, blood banks, and semen banks, while also managing a significant portfolio of marketable securities. The company is currently engaged in significant legal proceedings with the New York State Department of Health regarding the revocation of its operating licenses.
Key Financial Metrics
| Metric | 9 Months Ended Sep 30, 1995 | 9 Months Ended Sep 30, 1994 | 3 Months Ended Sep 30, 1995 | 3 Months Ended Sep 30, 1994 |
|---|---|---|---|---|
| Total Revenues | $3,325,114 | $3,380,590 | $991,284 | $1,035,717 |
| Operating Revenues | $1,188,521 | $1,406,679 | $254,928 | $452,771 |
| Net Income | $1,090,457 | $1,496,410 | $222,352 | $437,472 |
| EPS (Basic) | $0.22 | $0.29 | $0.05 | $0.08 |
| Cash from Operations | $961,531 | $1,369,874 | N/A | N/A |
| Total Assets | $38,250,788 | $35,012,638 | N/A | N/A |
| Total Liabilities | $6,608,895 | $5,813,458 | N/A | N/A |
| Shareholders' Equity | $31,641,893 | $29,199,180 | N/A | N/A |
| Loans Payable | $2,950,759 | $3,864,605 | N/A | N/A |
Portfolio Composition: As of September 30, 1995, marketable securities totaled $37,167,278 (fair value) with a cost basis of $26,901,936, resulting in net unrealized gains of $10,265,342.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased slightly for the nine-month period (1.6%) and the three-month period (4.3%) compared to 1994. Operating revenues specifically dropped significantly, down 15.5% for the nine months and 43.7% for the quarter, attributed to the partial closure of New York State facilities.
- Profitability: Net income decreased by 27.1% for the nine months and 49.1% for the quarter. This decline is driven by lower operating revenues and increased Selling, General, and Administrative expenses (up 47.9% for the nine months).
- Investment Gains: Gains on the sale of securities increased substantially to $483,083 for the nine months (up from $180,862 in 1994), partially offsetting the decline in operating income.
- Debt Reduction: Total loans payable decreased by approximately $913,846, primarily due to a $1.5 million repayment of a bank loan during the period.
- Share Repurchases: The company spent $1,908,302 on treasury stock purchases during the nine-month period, significantly increasing the value of treasury stock held.
Outlook, Risks, and Management Commentary
- Legal Contingencies: The company faces severe operational risks due to ongoing legal battles with the New York State Department of Health. Licenses for clinical laboratories, blood banks, and semen banks have been revoked or denied. DAXOR has filed appeals and initiated lawsuits, including a RICO action seeking $100 million in damages against the New York Blood Center and defamation suits seeking $50 million in total damages.
- Operational Impact: Management states that operational income has decreased because the company cannot obtain new clients due to license denials. However, existing storage clients continue to generate income.
- Liquidity and Capital Needs: The company reports adequate capital to sustain current operations and the New York blood banking facility. However, expanding the marketing of its Blood Volume Analyzer (BVA-100) or expanding blood banking operations nationwide would require additional capital.
- Strategic Initiatives: DAXOR is evaluating a proposal to purchase another private blood banking corporation and considering expanding its stake in US Cryobanks of Florida.
Key Investor Verification Points
- License Status: Verify the current status of the expedited appeal filed with the New York Appellate Division regarding the revocation of clinical and banking licenses.
- Legal Exposure: Assess the likelihood of success in the pending RICO and defamation lawsuits and the potential impact of the class action filed by depositors against the State Health Department.
- Revenue Sustainability: Confirm the extent to which operating revenues are dependent on the New York facilities and the timeline for potential re-opening.
- Capital Requirements: Evaluate the company's cash burn rate relative to its $69,692 cash balance and $37 million in marketable securities to determine if additional financing is needed for the BVA-100 marketing plan.
- Security Valuation: Review the composition of the $37 million securities portfolio to understand the concentration risk and the realizability of the $10.2 million in unrealized gains.